The research team is now monitoring 12 more participants who received higher doses of 150,000 and 250,000 cells. If no safety ...

A first-of-its-kind trial is testing adult stem cell transplants for advanced dry macular degeneration. Early results show ...

November is observed as Diabetic Eye Disease Awareness Month, a month dedicated to educating people about the serious eye ...

More than a third of older Singaporean adults have undiagnosed age-related eye diseases, increasing visual impairment risk.

A wireless implant helped patients with severe macular degeneration regain usable vision. The results point toward a new ...

The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.

The nods allow Regeneron to better compete with Roche, which stormed the market in 2022 with Vabysmo. The Swiss drugmaker's ...

It is unclear if eye drops to reduce immune responses of the eye surface, such as topical corticosteroids and cyclosporine, have any effect on the signs and symptoms of blepharitis at 4 to 12 weeks.

The clinical trial enrolled 38 adults aged 60 and older who had advanced geographic atrophy, the late stage of macular ...

Menlo Park resident Carmen Caricchio is on a quest to cure childhood inherited retinal diseases, a group of rare conditions that cause the degeneration of the retina and can lead to vision impairment ...

The approval is for Eylea to treat macular edema following retinal vein occlusion with up to every eight-week dosing after an initial dosing period. The FDA also approved a monthly dosing option for ...

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...